Lemtrada (Alemtuzumab)

Alemtuzumab is a type of medicine called an antibody. It's used to treat certain types of cancer, specifically some kinds of lymphoma. It works by attacking specific proteins on cancer cells.

Brand names:Campath, Lemtrada
Medication

What people taking Lemtrada (Alemtuzumab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lemtrada (Alemtuzumab) for MS (Multiple Sclerosis)?

NameHow it went

About Lemtrada (Alemtuzumab)

What It's For

Alemtuzumab is a prescription monoclonal antibody, a lab-made protein designed to attach to one specific target on cells. It is sold under two brand names for two very different diseases. Lemtrada is approved for adults with relapsing forms of multiple sclerosis (MS). That includes relapsing-remitting MS and secondary progressive MS that is still active, meaning it is still producing relapses or new inflammation. Because of its safety risks, Lemtrada is generally reserved for people whose MS has not been controlled well enough by two or more other MS medicines. It is not recommended for clinically isolated syndrome, a first episode of MS-like symptoms that does not yet meet the criteria for MS. Campath is approved as a single treatment for B-cell chronic lymphocytic leukemia (CLL), a slow-growing blood cancer. In the US it is not sold commercially. It is supplied only through a restricted program, the Campath Distribution Program, which ships it directly to registered doctors and hospitals. Most of this page describes Lemtrada, because its schedule and long-term monitoring differ substantially from the leukemia regimen.

How It Works

Alemtuzumab attaches to CD52, a marker on the surface of lymphocytes (the T and B white blood cells that direct immune attacks) and on some other immune cells. Once attached, it marks those cells for destruction, so lymphocyte counts fall sharply within about a month of each course. In MS, the immune system mistakenly attacks the protective coating of nerves in the brain and spinal cord. Removing large numbers of lymphocytes, and letting the immune system rebuild over the following months, is thought to reduce these attacks, although exactly how this helps in MS is not fully understood. B cells usually recover within about six months, while T cells return more slowly and are often still below normal a year later. Treatment can also lead the body to make autoantibodies, immune proteins that attack the body's own tissues. This is the source of alemtuzumab's distinctive long-term risk: autoimmune disease of the thyroid, blood platelets or kidneys that can appear months or years after the last dose. In CLL, the same targeting is used to help the immune system destroy leukemia cells.

Dosage & Administration

Lemtrada is given as an intravenous (IV) infusion, a slow drip into a vein, lasting about four hours, at a certified infusion center. Treatment comes in short courses rather than ongoing doses. The first course is one infusion a day for five days in a row; the second is one infusion a day for three days, given 12 months later. Some people later receive further three-day courses, each at least 12 months after the previous one. Preparation starts weeks ahead. Baseline blood, urine and thyroid tests are done, along with tuberculosis screening and a check of chickenpox immunity, and any needed vaccinations are finished at least six weeks before the first infusion. On the first three days of each course, a high-dose steroid is given just before the infusion to lessen infusion reactions. An antiviral medicine to prevent herpes infections starts on the first day and continues for at least two months, or longer until certain immune cells recover. Staff watch each person for at least two hours after every infusion. Because of its risks, Lemtrada is available only through a restricted safety program called a REMS (Risk Evaluation and Mitigation Strategy). Prescribers, infusion centers and patients all enroll, and patients agree to the long-term monitoring it requires. Campath for leukemia follows a different schedule: the dose is increased in steps over the first several days, then given three times a week for 12 weeks, with medicines to prevent pneumonia and herpes infections.

Side Effects

Infusion reactions are the most common problem. In MS studies, 92% of people had at least one. Rash, headache, fever, nausea, hives, itching, flushing, chills and tiredness are typical during or within a day or two of an infusion. Most are manageable, but reactions can start after leaving the infusion center, and they should be reported to the care team. Infections are more frequent too, especially colds, urinary tract infections, cold sores and shingles, and yeast infections of the mouth or vagina. Rarely, a stroke or a tear in an artery of the neck has occurred within three days of an infusion, most often within the first day. Call 911 for sudden facial drooping, weakness on one side of the body, trouble speaking, a sudden severe headache or sudden neck pain. Swelling of the mouth or throat or difficulty breathing after an infusion also needs emergency care. The longer-term concern is autoimmune disease. Thyroid problems are the most common, affecting more than a third of people treated in MS studies, and they can appear years later. Signs include unexplained weight change, a fast or pounding heartbeat, nervousness, worsening tiredness, eye swelling or feeling cold. Less often, people develop immune thrombocytopenia (ITP), a loss of the platelets that help blood clot, or anti-glomerular basement membrane (anti-GBM) disease, an immune attack on the kidneys' filtering units that can also cause bleeding in the lungs. Contact the care team right away for easy bruising, tiny red or purple spots on the skin, bleeding that is hard to stop, unusually heavy periods, coughing up blood, new swelling of the legs or feet, or blood in the urine or darker urine. Yellowing of the skin or eyes also needs prompt attention.

Interactions & Warnings

Lemtrada carries the FDA's most serious (boxed) warning for four risks: serious autoimmune conditions, serious infusion reactions, stroke, and cancer. The cancers of concern are thyroid cancer, melanoma and lymphomas (cancers of the lymphatic system). A skin exam before treatment and every year afterward is recommended, and a new lump in the neck, hoarseness that does not go away or trouble swallowing should be reported. It should not be used by people with HIV, by anyone with an active infection, or by people who have had a severe allergic reaction to alemtuzumab. Taking it with other medicines that suppress the immune system or treat cancer can add to the risk of infection. Live vaccines should not be given after a course, which is why vaccinations are brought up to date beforehand. Listeria, a bacterium found in some foods, has caused serious infections, including meningitis, after treatment. People are advised to avoid or thoroughly heat deli meats, unpasteurized dairy products, soft cheeses and undercooked meat, seafood or poultry, starting before the first course. Fever, a stiff neck, headache or confusion should be reported promptly. Yearly HPV (human papillomavirus) screening is recommended for women. Women who could become pregnant should use effective contraception during each course and for four months afterward. Thyroid disease caused by alemtuzumab can complicate a pregnancy, and thyroid antibodies can cross the placenta and affect the baby even when the pregnancy begins after treatment, so pregnancy plans are worth discussing early. Campath, used at higher and more frequent doses for leukemia, carries its own boxed warning for severe, sometimes fatal, drops in blood counts, infusion reactions and infections.

What to Expect

Lemtrada differs from most MS treatments because many people receive only two courses, a year apart, instead of taking a medicine daily or receiving infusions every few months. In the two main studies, people given Lemtrada had about half as many relapses over two years as people using interferon beta-1a injections, an older standard MS treatment. In the study of people who had already relapsed on another medicine, fewer had worsening disability at two years (13% compared with 21%); in the study of people who had not been treated before, disability results did not differ meaningfully. Some people need a third or later course if MS activity returns. The treatment days are brief, but follow-up is long. Blood and urine tests are done every month, and thyroid tests every three months, until 48 months after the last infusion, because autoimmune problems caught early are more treatable. In an early study, before monthly blood tests were required, one person's ITP went unrecognized and they died of bleeding in the brain. After the four years, testing continues if symptoms suggest an autoimmune problem. The REMS program provides a patient safety card to carry in case of an emergency. Lymphocyte counts are lowest about a month after each course and recover gradually over the following year, which is why antiviral protection continues for at least two months after each course.

Questions to Ask Your Doctor

  1. 1.Why is Lemtrada a good fit for my MS compared with other options, given the medicines I have already tried?
  2. 2.How will my monthly blood and urine tests be arranged for the next four years, and who will review the results?
  3. 3.Which symptoms after an infusion should I report, and who do I contact after hours?
  4. 4.How could treatment affect my thyroid and my plans for pregnancy?
  5. 5.Are my vaccinations up to date, and which foods should I avoid because of Listeria?

Last reviewed • Oct 2026

Educational content, not medical advice.